HTA of genetic testing for susceptibility to venous thromboembolism in Italiy

S Betti; A Boccia; Stefania Boccia; C Casella; D Coviello; E Di Maria; Maria Luisa Di Pietro; E Giorgio; M. R. Gualano; G Ivaldi; A Izzotti; Lamberto Manzoli; C Marzuillo; A Melegaro; A Miani; Walter Ricciardi; Benedetto Simone; R Tarricone; A. A. Teleman; V Uliana; M Vercelli; P Villari; T. Za

HTA of genetic testing for susceptibility to venous thromboembolism in Italiy

S Betti, A Boccia, Stefania Boccia, C Casella, D Coviello, E Di Maria, Maria Luisa Di Pietro, E Giorgio, M. R. Gualano, G Ivaldi, A Izzotti, Lamberto Manzoli, C Marzuillo, A Melegaro, A Miani, Walter Ricciardi, Benedetto Simone, R Tarricone, A. A. Teleman, V UlianaM Vercelli, P Villari, T. Za

Risultato della ricerca: Working paper

Abstract

Health Technology Assessment (HTA) is important to address the health policy decisions and to make the translational process possible. HTA is a multidisciplinary method that systematically examines the epidemiological, medical, economic, organizational, social and ethical implications of the application of a health technology – usually a drug, medical device or clinical/surgical procedure. This HTA report aims to assess the current scenario of genetic testing provided for the susceptibility to VTE in Italy. The project is based on the ACCE (Analytic validity, Clinical validity, Clinical utility, Ethical, legal and social aspects) model, which was developed by the National Office of Public Health Genomics, CDC in 2004. By using a comprehensive approach, the report considered all the possible implications related to the utilization of genetic testing for the susceptibility to VTE.

Lingua originale	English
Pagine	S1-S72
Numero di pagine	72
Stato di pubblicazione	Pubblicato - 2012

Keywords

HTA
Italy
genetic testing
venous thromboembolism

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Betti, S., Boccia, A., Boccia, S., Casella, C., Coviello, D., Di Maria, E., Di Pietro, M. L., Giorgio, E., Gualano, M. R., Ivaldi, G., Izzotti, A., Manzoli, L., Marzuillo, C., Melegaro, A., Miani, A., Ricciardi, W., Simone, B., Tarricone, R., Teleman, A. A., ... Za, T. (2012). HTA of genetic testing for susceptibility to venous thromboembolism in Italiy. (pagg. S1-S72).

@techreport{2b71b7541ee84c3fbd64aac2e0c5fd82,

title = "HTA of genetic testing for susceptibility to venous thromboembolism in Italiy",

abstract = "Health Technology Assessment (HTA) is important to address the health policy decisions and to make the translational process possible. HTA is a multidisciplinary method that systematically examines the epidemiological, medical, economic, organizational, social and ethical implications of the application of a health technology – usually a drug, medical device or clinical/surgical procedure. This HTA report aims to assess the current scenario of genetic testing provided for the susceptibility to VTE in Italy. The project is based on the ACCE (Analytic validity, Clinical validity, Clinical utility, Ethical, legal and social aspects) model, which was developed by the National Office of Public Health Genomics, CDC in 2004. By using a comprehensive approach, the report considered all the possible implications related to the utilization of genetic testing for the susceptibility to VTE.",

keywords = "HTA, Italy, genetic testing, venous thromboembolism, HTA, Italy, genetic testing, venous thromboembolism",

author = "S Betti and A Boccia and Stefania Boccia and C Casella and D Coviello and {Di Maria}, E and {Di Pietro}, {Maria Luisa} and E Giorgio and Gualano, {M. R.} and G Ivaldi and A Izzotti and Lamberto Manzoli and C Marzuillo and A Melegaro and A Miani and Walter Ricciardi and Benedetto Simone and R Tarricone and Teleman, {A. A.} and V Uliana and M Vercelli and P Villari and T. Za",

year = "2012",

language = "English",

pages = "S1--S72",

type = "WorkingPaper",

}

Betti, S, Boccia, A, Boccia, S, Casella, C, Coviello, D, Di Maria, E, Di Pietro, ML, Giorgio, E, Gualano, MR, Ivaldi, G, Izzotti, A, Manzoli, L, Marzuillo, C, Melegaro, A, Miani, A, Ricciardi, W, Simone, B, Tarricone, R, Teleman, AA, Uliana, V, Vercelli, M, Villari, P & Za, T 2012 'HTA of genetic testing for susceptibility to venous thromboembolism in Italiy' pagg. S1-S72.

TY - UNPB

T1 - HTA of genetic testing for susceptibility to venous thromboembolism in Italiy

AU - Betti, S

AU - Boccia, A

AU - Boccia, Stefania

AU - Casella, C

AU - Coviello, D

AU - Di Maria, E

AU - Di Pietro, Maria Luisa

AU - Giorgio, E

AU - Gualano, M. R.

AU - Ivaldi, G

AU - Izzotti, A

AU - Manzoli, Lamberto

AU - Marzuillo, C

AU - Melegaro, A

AU - Miani, A

AU - Ricciardi, Walter

AU - Simone, Benedetto

AU - Tarricone, R

AU - Teleman, A. A.

AU - Uliana, V

AU - Vercelli, M

AU - Villari, P

AU - Za, T.

PY - 2012

Y1 - 2012

N2 - Health Technology Assessment (HTA) is important to address the health policy decisions and to make the translational process possible. HTA is a multidisciplinary method that systematically examines the epidemiological, medical, economic, organizational, social and ethical implications of the application of a health technology – usually a drug, medical device or clinical/surgical procedure. This HTA report aims to assess the current scenario of genetic testing provided for the susceptibility to VTE in Italy. The project is based on the ACCE (Analytic validity, Clinical validity, Clinical utility, Ethical, legal and social aspects) model, which was developed by the National Office of Public Health Genomics, CDC in 2004. By using a comprehensive approach, the report considered all the possible implications related to the utilization of genetic testing for the susceptibility to VTE.

AB - Health Technology Assessment (HTA) is important to address the health policy decisions and to make the translational process possible. HTA is a multidisciplinary method that systematically examines the epidemiological, medical, economic, organizational, social and ethical implications of the application of a health technology – usually a drug, medical device or clinical/surgical procedure. This HTA report aims to assess the current scenario of genetic testing provided for the susceptibility to VTE in Italy. The project is based on the ACCE (Analytic validity, Clinical validity, Clinical utility, Ethical, legal and social aspects) model, which was developed by the National Office of Public Health Genomics, CDC in 2004. By using a comprehensive approach, the report considered all the possible implications related to the utilization of genetic testing for the susceptibility to VTE.

KW - HTA

KW - Italy

KW - genetic testing

KW - venous thromboembolism

KW - HTA

KW - Italy

KW - genetic testing

KW - venous thromboembolism

UR - https://publicatt.unicatt.it/handle/10807/40256

M3 - Working paper

SP - S1-S72

BT - HTA of genetic testing for susceptibility to venous thromboembolism in Italiy

ER -

HTA of genetic testing for susceptibility to venous thromboembolism in Italiy

Abstract

Keywords

OSS delle Nazioni Unite

Altri file e collegamenti

Fingerprint

Cita questo